TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q0914ex32i_tianyinpharma.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q0914ex32ii_tianyinpharma.htm CERTIFICATION]

By | 2016-03-19T15:04:02+00:00 December 31st, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments
Read More

TPI [TIANYIN PHARMACEUTICAL] 10-Q:

[] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q0914ex32i_tianyinpharma.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q0914ex32ii_tianyinpharma.htm CERTIFICATION]

By | 2016-03-19T15:04:55+00:00 December 31st, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 8-K: (Original Filing)

[Item 5.07 Submission of Matters to a Vote of Security Holders. On December 29, 2014, China Pharma Holdings, Inc. (the “Company”) held its 2014 annual shareholders meeting (the “Annual Meeting”). At the Annual Meeting, the only proposal submitted to a vote of the shareholders of the Company was the election of three persons to the Board of Directors of the]

By | 2016-03-28T19:24:01+00:00 December 31st, 2014|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13D/A: (Original Filing)

[SCHEDULE 13D (Amendment No. 04 )* SKYSTAR BIO-PHARMACEUTICAL CO (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) John M. Gregory, SJ Strategic Investments, LLC 340 MARTIN LUTHER KING, JR. BLVD., Suite 200 BRISTOL, Tennessee 37620 Phone : (423) 989-8133 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 10, 2014]

By | 2016-03-27T15:33:56+00:00 December 15th, 2014|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13D/A: SCHEDULE 13D (Amendment No. 04 )* SKYSTAR BIO-PHARMACEUTICAL

[SCHEDULE 13D (Amendment No. 04 )* SKYSTAR BIO-PHARMACEUTICAL CO (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) John M. Gregory, SJ Strategic Investments, LLC 340 MARTIN LUTHER KING, JR. BLVD., Suite 200 BRISTOL, Tennessee 37620 Phone : (423) 989-8133 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 10, 2014]

By | 2016-03-27T15:34:49+00:00 December 15th, 2014|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Read More

TPI [TIANYIN PHARMACEUTICAL] 10-K: (Original Filing)

[TIANYIN PHARMACEUTICAL CO., INC FORM 10-K INDEX Page PART I Item 1 Description of Business 3 Item 1A Risk Factors 14 Item 1B Unresolved Staff Comments 25 Item 2 Description of Property 26 Item 3 Legal Proceedings 26 Item 4 Removed and Reserved 26 PART II Item 5 Market for Common Equity and Related Stockholder Matters and Issuer Purchases of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer EX-32.1 4 f10k2014ex32i_tianyinpharma.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer EX-32.2 5 f10k2014ex32ii_tianyinpharma.htm CERTIFICATION]

By | 2016-03-19T15:06:43+00:00 December 9th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments
Read More

TPI [TIANYIN PHARMACEUTICAL] 10-K: TIANYIN PHARMACEUTICAL CO., INC FORM 10-K INDEX Page

[TIANYIN PHARMACEUTICAL CO., INC FORM 10-K INDEX Page PART I Item 1 Description of Business 3 Item 1A Risk Factors 14 Item 1B Unresolved Staff Comments 25 Item 2 Description of Property 26 Item 3 Legal Proceedings 26 Item 4 Removed and Reserved 26 PART II Item 5 Market for Common Equity and Related Stockholder Matters and Issuer Purchases of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer EX-32.1 4 f10k2014ex32i_tianyinpharma.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer EX-32.2 5 f10k2014ex32ii_tianyinpharma.htm CERTIFICATION]

By | 2016-03-19T15:07:46+00:00 December 9th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)

[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 3, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:11:26+00:00 December 5th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More
Skip to toolbar